Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas and Pfizer, Inc., Exelixis, Inc.; and Sanofi Genzyme.

Community Practice Connections™: Selecting and Sequencing Therapies Through the Prostate Cancer Continuum: An Expert Tumor Board Discussion

Release Date: April 01, 2020
Expiration Date: April 01, 2021

Activity Overview

The past decade has witnessed substantial advances in the treatment of advanced/metastatic prostate cancer due to growing insight into the biology of the disease. Treatment of prostate cancer is challenging because of the heterogeneity of tumors, numerous treatment regimens available, and the lack of clear recommendations about which treatment should be used at various time points during disease progression. Clinicians face the difficult task of treatment selection and sequencing of drugs, which requires careful consideration of the patient’s clinical profile as well as the risks and benefits of therapy to maximize effectiveness while minimizing toxicity.

This enduring online activity, entitled Community Practice Connections™: Selecting and Sequencing Therapies Through the Prostate Cancer Continuum: An Expert Tumor Board Discussion, is designed to provide updates on the latest data applicable to the care of patients with prostate cancer. Each module covers how to select and sequence therapies throughout the prostate cancer care continuum using current and emerging treatment options for patients with prostate cancer across the spectrum of disease, including castration-sensitive and -resistant, as well as nonmetastatic and metastatic prostate cancer. This activity will aid the integration of cutting-edge data and evidence-based advances in prostate cancer care into clinical practice.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas and Pfizer, Inc., Exelixis, Inc.; and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, urologists, surgical oncologists, and radiation oncologists interested in the treatment of prostate cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with prostate cancer are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Develop and implement personalized treatment plans for patients with early-stage and advanced prostate cancer
  • Compare and contrast the efficacy and safety profiles of available therapies for prostate cancer management
  • Utilize key evidence to select and sequence therapies along the prostate cancer disease continuum
  • Summarize data sets from key clinical trials investigating novel agents for prostate cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCOM
Deputy Director
Associate Director for Clinical Research
University of Virginia Cancer Center
Co-Director and Section Head of Medical Oncology
Paul Mellon Urologic Cancer Research Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Disclosures: Grant/Research Support: Merck & Co., Modra Pharmaceuticals, Pfizer, Seattle Genetics; Consultant: Astellas Pharma, Janssen, Novartis, Seattle Genetics, Roche.

Celestia S. Higano, MD, FACP
Celestia S. Higano, MD, FACP
Professor of Medicine and Urology
University of Washington School of Medicine
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosures: Grant/Research Support: Aragon Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, Clovis, Emergent, Ferring Pharmaceuticals, Hoffman-La Roche, Pfizer; Consultant: Advantagene, AstraZeneca, Bayer, Blue Earth Diagnostics, Carrick Therapeutics, Clovis , Dendreon, Ferring Pharmaceuticals, Hinova, Janssen, Merck, Novartis, Pfizer.

Philip Kantoff, MD
Philip Kantoff, MD
Chairman of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical School
George J. Bosl Professor of Medicine
New York, NY

Disclosures: Consultant: Bavarian Nordic Immunotherapeutics, GE Healthcare, Janssen, OncoCell MDx, Progenity, Seer Biosciences, Tarveda Therapeutics (previously Blend); Other: Context Therapeutics LLC (member of company board and investment interest), Druggability Technologies (scientific advisory and investment interest), Genentech/Roche and Merck & Co Inc, (data safety monitoring board), Placon and Seer Biosciences (investment interest).

Oliver Sartor, MD
Oliver Sartor, MD
C. E. & Bernadine Laborde Professor for Cancer Research
Departments of Medicine and Urology
Assistant Dean for Oncology
Tulane University School of Medicine
Medical Director, Tulane Cancer Center
New Orleans, LA

Disclosures: Grant/Research Support: AstraZeneca, Bayer, Dendreon, Endocyte, Innocrin, Invitae, Janssen, Merck, Sanofi, SOTIO; Consultant: Advanced Accelerator Applications (AAA), Astellas Pharma, AstraZeneca, Bayer, Bellicum Pharmaceuticals, Blue Earth Diagnostics, Bavarian Nordic, Bristol-Myers Squibb, Clovis, Constellation Pharmaceuticals, Dendreon, EMD Serono, Janssen, Myraid, Myovant Sciences, Novartis, Noxopharm, Pfizer, Progenics Pharmaceuticals, Sanofi; Shareholder: AbbVie, Cardinal Health, GlaxoSmithKline, Eli Lilly and Company, PSMA Therapeutic Group, UnitedHealth Group.

Neal Shore, MD, FACS
Neal Shore, MD, FACS
Director, CPI
Carolina Urologic Research Center
Oncologist and Urologist
Atlantic Urology Clinics
Myrtle Beach, SC

Disclosures: Grant/Research Support: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Ferring Pharmaceuticals, Foundation Medicine, Janssen, Merck, Myovant Sciences, Nymox Pharmaceutical Corporation, Pfizer, Sanofi Genzyme, Tolmar; Consultant: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Ferring Pharmaceuticals, Foundation Medicine, Janssen, Merck, Myovant Sciences, Nymox Pharmaceutical Corporation, Pfizer, Sanofi Genzyme, Tolmar.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By